Graphite Bio be­gins SCD cell ther­a­py tri­al; Syn­thet­ic Bi­o­log­ic­s' fu­ture rests on VCN ac­qui­si­tion

Graphite Bio has dosed its first sick­le cell dis­ease pa­tient with its cell ther­a­py, the Bay Area biotech an­nounced this morn­ing.

In its proof-of-con­cept CEDAR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.